Pfizer's Zavzpret, a nasal spray for migraines that can relieve symptoms in just 30 minutes has been approved by US Food and Drug Administration (FDA) on Thursday and may be available in pharmacies from July. Although the cost of the drug has not yet been disclosed by the New York pharma company.
Migraine is a neurological condition that is characterized by recurrent moderate-to-severe throbbing or pulsating headaches, usually affecting one side of the head. It can also be accompanied by other symptoms, such as nausea, vomiting, sensitivity to light or sound, and visual disturbances. Migraines can last for several hours or even days and can be triggered by various factors, such as stress, hormonal changes, certain foods or drinks, lack of sleep, and changes in weather or altitude. While there is currently no known cure for migraines, the approval of Zavzpret, based on data from a late-stage study, is welcome news for the 39 million people affected by the condition in the United States, according to the Migraine Research Foundation.
In the study, a 10mg dose of the drug was found to be more effective than a placebo in relieving migraine pain after two hours. Moreover, the spray eased symptoms within 15-30 minutes and lasted up to 48 hours after administration.
As a nasal spray with rapid drug absorption, Zavzpret offers an alternative treatment option for individuals who need pain relief and cannot take oral medications due to nausea or vomiting, enabling them to return to normal function quickly.
Comments